Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CMV-Ig · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| CMV-Ig | DRUG | Drug: CMV-Ig |
Inclusion Criteria: * Lung transplant * Hypogammaglobulinemia
CMV-Ig is an investigational small molecule being studied for hypogammaglobulinemia, a condition marked by low antibody levels. It is being developed by Community Health Systems, Inc. (CYH) and is currently in Phase 2 clinical development. It is not approved and remains under investigation.
CMV-Ig is being developed by Community Health Systems, Inc., a company traded under the ticker CYH. The drug is in Phase 2 clinical development for hypogammaglobulinemia. It is an investigational small molecule and has not been approved for any use.
CMV-Ig is in Phase 2 clinical development. It is being studied for hypogammaglobulinemia. The drug is investigational and has not been approved by regulatory authorities. One Phase 2 trial has been completed, and it remains in active development.
CMV-Ig has one completed Phase 2 trial, NCT00137748, titled "Cytomegalovirus Hyperimmune Globulin (CMV-Ig) Replacement in Hypogammaglobulinemic Lung Transplant Recipients." The trial enrolled 50 participants in the United States and was uncontrolled, meaning there was no comparator arm.
Yes, CMV-Ig is also known as Cytomegalovirus Hyperimmune Globulin. The completed Phase 2 trial NCT00137748 used this full name. The drug is being studied for hypogammaglobulinemia and is in Phase 2 development by Community Health Systems, Inc.